E.G7-OVA
E.G7-OVA是建系於1988年的C57BL/6N小鼠淋巴瘤細胞系[1]。E.G7-OVA細胞包含着單個拷貝的質粒,並且持續地合成和分泌着卵蛋白素。使用對E.G7-OVA細胞免疫的C57BL/6小鼠,產生了對OVA 258-276肽擁有特異性H-2Kb抗原限制性細胞毒性的淋巴細胞[1][2]。該細胞系目前應用作研究小鼠中,細胞毒性T細胞的主要組織相容性複合體I類限制性反應的模型[1]。有研究中評估了對C-卵蛋白素呈現陽性反應的重組桿狀病毒組合疫苗(FrC-OVA-BV),刺激小鼠抗EG7-OVA腫瘤細胞的免疫反應[3]。
參考資料
- ^ 1.0 1.1 1.2 Moore, MW; Carbone, FR; Bevan, MJ. Introduction of soluble protein into the class I pathway of antigen processing and presentation.. Cell. 1988-09-09, 54 (6): 777–85 [2019-12-25]. PMID 3261634. doi:10.1016/s0092-8674(88)91043-4. (原始内容存档于2019-12-25).
- ^ Zhou, F; Rouse, BT; Huang, L. Prolonged survival of thymoma-bearing mice after vaccination with a soluble protein antigen entrapped in liposomes: a model study.. Cancer research. 1992-11-15, 52 (22): 6287–91 [2019-12-25]. PMID 1384958. (原始内容存档于2019-12-25).
- ^ Kondou, Keigo; Suzuki, Tomoyuki; Chang, Myint Oo; Takaku, Hiroshi. Recombinant baculovirus expressing the FrC-OVA protein induces protective antitumor immunity in an EG7-OVA mouse model. Journal of Biological Engineering. 2019-10-22, 13 (1) [2019-12-25]. PMID 31649751. doi:10.1186/s13036-019-0207-y. (原始内容存档于2019-12-25).